Ryan J. Watts, President and CEO at Denali Therapeutics Inc. (DNLI), sold 40,000 shares at $27.69 ($1.1M) on 2024-10-18, disclosed to the SEC on 2024-10-22.
Scheduled sale ($1.1M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DNLI | SELL | 2025-01-08 | $1.5M | — | Filing → |
| DNLI | SELL | 2024-08-22 | $108K | — | Filing → |
| DNLI | SELL | 2024-02-15 | $332K | — | Filing → |